Navigation Links
PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
Date:7/9/2009

n of the FDA feedback to BARDA should enable the agency to recommence contract negotiations with the Company. In the meantime, development activities for the SparVax(TM) program are continuing pursuant to the Company's existing development contract for SparVax(TM), which was transferred from the National Institutes of Health to BARDA on April 1, 2009."

About SparVax(TM)

SparVax(TM) is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection. This product employs modern vaccine technology to provide a highly purified and well characterized modern vaccine for intended use by the military and civilian Strategic National Stockpile. Phase I and Phase II clinical trials involving more than 750 healthy human subjects have been completed and showed that SparVax(TM) appears to be well tolerated and induces an immune response in humans. These studies suggest that three doses of SparVax(TM), administered several weeks apart, should be sufficient to induce protective immunity. In preclinical studies SparVax(TM) has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain. The clinical and non-clinical studies for SparVax(TM) have been carried out under contracts with the National Institute of Allergy and Infectious Diseases and the National Institutes of Health.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a full
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. New Generation Biofuels Signs Letter of Intent with Instituto Costarricense de Electricidad (ICE) of Costa Rica
3. A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd.
4. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
5. Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform
6. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
7. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
8. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
9. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
10. City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
11. SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... patent-protected processes to develop and market advanced products and ... Medicine, Ophthalmic and Dental sectors of healthcare, announced today ... Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)...  Merck KGaA, Darmstadt, Germany , ... in the healthcare, life science and performance materials sectors, ... development and launch of promising new fullerene derivatives for ... Darmstadt, Germany , is pursuing many ... Novel derivatives: highly stable, easy to process and ...
(Date:8/3/2015)... , Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: ... to treat life-threatening diseases, today announced that it will ... and webcast on Thursday, August 13, 2015 at 4:30 ... will follow the release of fiscal 2016 first quarter ... available approximately two hours after the call at the ...
(Date:8/3/2015)... Md. , Aug. 3, 2015   Intrexon ... will release first half and second quarter 2015 financial ... th , 2015.  The Company will host a conference ... and provide a general business update. The ... US) and 1-412-902-4262 (International), and asking to join the ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2
... today announced that Garry W. Rogerson, President and CEO,will speak ... Thursday,December 4, 2008 at 9:45 a.m. Eastern time. , ... presentation will be publicly available from Varian,Inc.,s Web site at ... on "Investors." An archived replay will be available to ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) will host ... its drug development programs and financial results,for the third ... Kuo,MD, MBA, will host the call and there will ... To participate in the teleconference, please ...
... Nov. 20 Cyntellect, a privately-held life,sciences company ... manipulation and purification systems, announced today that it ... University of Florida ,Interdisciplinary Center for Biotechnology Research. ... research areas including the purification and analysis of,cancer ...
Cached Biology Technology:Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 2Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 3Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 4Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 5Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 6Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 7University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells 2University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... at the heart of a novel agricultural technique to manage ... can be used to turn carbon dioxide emissions into soil-enriching ... thrives in tropical areas, such as West Africa. ... in dry, acidic soil and treated with a combination of ...
... Researchers at the Instituto Andaluz de Ciencias de la Tierra ... was recently published in the prestigious journal Reviews of ... from 11 different countries has published the most comprehensive study ... the most important contemporary issues in a field of research ...
... Endocrine Society,s Journal of Clinical Endocrinology and Metabolism ... reduce the rate of mortality in seniors, therefore providing ... During the last decade, there has been increasing ... It is well known that calcium with vitamin D ...
Cached Biology News:Bugs have key role in farming approach to storing CO2 emissions 2Spanish scientist participate in the most comprehensive study ever done on ice 2
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rab1A...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: